252 related articles for article (PubMed ID: 33358561)
1. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.
Mahadevan A; Moningi S; Grimm J; Li XA; Forster KM; Palta M; Prior P; Goodman KA; Narang A; Heron DE; Lo SS; Urbanic J; Herman JM
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):206-216. PubMed ID: 33358561
[TBL] [Abstract][Full Text] [Related]
2. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards.
Soltys SG; Grimm J; Milano MT; Xue J; Sahgal A; Yorke E; Yamada Y; Ding GX; Li XA; Lovelock DM; Jackson A; Ma L; El Naqa I; Gibbs IC; Marks LB; Benedict S
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):112-123. PubMed ID: 33516580
[TBL] [Abstract][Full Text] [Related]
4. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Lee P; Loo BW; Biswas T; Ding GX; El Naqa IM; Jackson A; Kong FM; LaCouture T; Miften M; Solberg T; Tome WA; Tai A; Yorke E; Li XA
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):160-171. PubMed ID: 30954520
[TBL] [Abstract][Full Text] [Related]
5. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
7. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
Jiang W; Haque W; Verma V; Butler EB; Teh BS
Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
[No Abstract] [Full Text] [Related]
9. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
[TBL] [Abstract][Full Text] [Related]
10. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma.
Liu F; Brown DR; Munley MT
Radiother Oncol; 2024 May; 194():110223. PubMed ID: 38467342
[TBL] [Abstract][Full Text] [Related]
11. Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors.
Stumpf PK; Yorke ED; El Naqa I; Cuneo KC; Grimm J; Goodman KA
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):217-226. PubMed ID: 33864824
[TBL] [Abstract][Full Text] [Related]
12. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674
[TBL] [Abstract][Full Text] [Related]
14. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases.
Redmond KJ; Gui C; Benedict S; Milano MT; Grimm J; Vargo JA; Soltys SG; Yorke E; Jackson A; El Naqa I; Marks LB; Xue J; Heron DE; Kleinberg LR
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):53-67. PubMed ID: 33390244
[TBL] [Abstract][Full Text] [Related]
15. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
Holyoake DL; Ward E; Grose D; McIntosh D; Sebag-Montefiore D; Radhakrishna G; Patel N; Silva M; Mukherjee S; Strauss VY; Odondi L; Fokas E; Melcher A; Hawkins MA
BMC Cancer; 2016 Sep; 16(1):728. PubMed ID: 27619800
[TBL] [Abstract][Full Text] [Related]
16. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
17. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
[TBL] [Abstract][Full Text] [Related]
18. Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis.
Zaorsky NG; Lehrer EJ; Handorf E; Meyer JE
Am J Clin Oncol; 2019 Jan; 42(1):46-55. PubMed ID: 29965809
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
